Evidence map›Paper›PMID 33510639›Full record

ReviewFrontiers in pharmacology2020

Overview of OxLDL and Its Impact on Cardiovascular Health: Focus on Atherosclerosis.

Anastasia V Poznyak, Nikita G Nikiforov, Alexander M Markin, Dmitry A Kashirskikh, Veronika A Myasoedova, Elena V Gerasimova, Alexander N Orekhov

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 242 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
242citing papers in PubMed, 2 pooled it
19.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

242 citing papers in PubMed, 2 syntheses or guidelines pooled it, 350 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Lipid Metabolism Modulation by a Flavonoid-StandardizedJournal of experimental pharmacology · 2026
    Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. HarnessingFood science & nutrition · 2026
    Review
  10. Review
  11. Review
  12. Macrophage PIM1 Drives Atherosclerosis by Enhancing Foam Cell Formation Via CD36.Arteriosclerosis, thrombosis, and vascular biology · 2026
    Article
  13. Olfactomedin 2 Promotes Atherosclerosis by Eliciting Smooth Muscle Foam Cell Formation.Arteriosclerosis, thrombosis, and vascular biology · 2026
    Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. The Oxidative Stress: Origin and Role in Aging and Diseases.Antioxidants (Basel, Switzerland) · 2026
    Review

182 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Anastasia V PoznyakInstitute for Atherosclerosis Research, Skolkovo Innovative Center, Moscow, Russia.
Nikita G NikiforovCentre of Collective Usage, Institute of Gene Biology, Russian Academy of Sciences, Moscow, Russia.
Alexander M MarkinLaboratory of Cellular and Molecular Pathology of the Cardiovascular System, Institute of Human Morphology, Moscow, Russia.
Dmitry A KashirskikhLaboratory of Cellular and Molecular Pathology of the Cardiovascular System, Institute of Human Morphology, Moscow, Russia.
Veronika A MyasoedovaLaboratory of Angiopathology, Institute of General Pathology and Pathophysiology, Moscow, Russia.
Elena V GerasimovaDepartment of Systemic Rheumatic Diseases, V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia.
Alexander N OrekhovInstitute for Atherosclerosis Research, Skolkovo Innovative Center, Moscow, Russia.
Institute for Atherosclerosis Research · RUResearch Institute of Human Morphology · RUInstitute of Gene Biology · RUResearch Institute of General Pathology and Pathophysiology, the Russian Academy of Medical Sciences · RUVA Nasonova Scientific Research Institute of Rheumatology · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiovascular pathologies maintain the leading position in mortality worldwide. Atherosclerosis is a chronic disease that can result in a variety of serious complications, such as myocardial infarction, stroke, and cardiovascular disease. Inflammation and lipid metabolism alterations play a crucial role in atherogenesis, but the details of relationships and causality of these fundamental processes remain not clear. The oxidation of LDL was considered the main atherogenic modification of LDL within the vascular wall for decades. However, recent investigations provided a growing body of evidence in support of the multiple LDL modification theory. It suggests that LDL particles undergo numerous modifications that change their size, density, and chemical properties within the blood flow and vascular wall. Oxidation is the last stage in this cascade resulting in the atherogenic properties. Moreover, recent investigations have discovered that oxLDL may have both anti-inflammatory and pro-inflammatory properties. Oxidized LDL can trigger inflammation through the activation of macrophages and other cells. After all, oxidized LDL is still a promising object for further investigations that have the potential to clarify the unknown parts of the atherogenic process. In this review, we discuss the role of oxLDL in atherosclerosis development on different levels.

Indexed as

atherosclerosiscardiovascular diseaselow-density lipoproteinoxidative stressoxLDL

Identifiers

PMID33510639
PMCPMC7836017
OpenAlexW3120161822

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.